Author

Stefan Schwabe

Observed names: S. K. Schwabe, S. Schwabe, Schwabe, Stefan, Stefan K. Schwabe, Stefan Schwabe Md

Institution: Supernus Pharmaceuticals (United States)

Observed institutions: Virginia Commonwealth University, SUNY Upstate Medical University, Leibniz Institute for Solid State and Materials Research, Novartis (United States), Supernus Pharmaceuticals (United States), Janssen Research & Development (United States), University of Florence, Technische Universität Dresden

ORCID: 0000-0002-1426-2584

Observed ORCID: 0000-0002-1426-2584

OpenAlex ID: A5035263710

Hyponatremia Associated with Carbamazepine and Oxcarbazepine Therapy: A Review

1994 · Th. Van Amelsvoort, R. Bakshi, et al. · Epilepsia · 255

Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials

2004 · The Topiramate Diabetic Neuropathic Pain Study Group*, U. Thienel, et al. · Acta Neurologica Scandinavica · 185

Pharmacokinetic Interactions of Topiramate

2004 · Meir Bialer, Dennis R Doose, et al. · Clinical Pharmacokinetics · 184

Effect of Topiramate or Carbamazepine on the Pharmacokinetics of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol in Healthy Obese and Nonobese Female Subjects

2003 · Dennis R. Doose, Shean‐Sheng Wang, et al. · Epilepsia · 163

PDF

Randomized dose-controlled study of topiramate as first-line therapy in epilepsy

2005 · S. Arroyo, W. E. Dodson, et al. · Acta Neurologica Scandinavica · 120

New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties

2020 · Chungping Yu, Jennie Garcia-Olivares, et al. · Journal of Experimental Pharmacology · 100

PDF

A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children

2020 · Azmi Nasser, Tesfaye Liranso, et al. · Clinical Therapeutics · 87

PDF

The Neurotoxicity Scale: The validity of a patient-based scale, assessing neurotoxicity

1995 · A.P. Aldenkamp, G. Baker, et al. · Epilepsy Research · 69

Influence of Single and Repeated Doses of Oxcarbazepine on the Pharmacokinetic Profile of Felodipine

1993 · G. Zaccara, P. F. Gangemi, et al. · Therapeutic Drug Monitoring · 66

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

2019 · Janet K. Johnson, Tesfaye Liranso, et al. · Journal of Attention Disorders · 64

Topiramate and Lamotrigine Pharmacokinetics during Repetitive Monotherapy and Combination Therapy in Epilepsy Patients

2003 · Dennis R. Doose, Martin J. Brodie, et al. · Epilepsia · 59

Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status

2021 · Robert L. Findling, Shawn A. Candler, et al. · CNS Drugs · 58

PDF

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder

2022 · Azmi Nasser, Joseph T. Hull, et al. · CNS Drugs · 57

PDF

Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial

2021 · Azmi Nasser, Tesfaye Liranso, et al. · Clinical Therapeutics · 56

Challenges in the Clinical Development of New Antiepileptic Drugs

2002 · Stefan K. Schwabe · Therapeutic Drug Monitoring · 53

A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder

2021 · Azmi Nasser, Tesfaye Liranso, et al. · Journal of Clinical Psychopharmacology · 47

A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.

2021 · Azmi Nasser, Tesfaye Liranso, et al. · PubMed Central · 36

Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults

2020 · Shamia L. Faison, Nicholas Fry, et al. · Clinical Drug Investigation · 24

PDF

Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder

2021 · Azmi Nasser, Roberto Gomeni, et al. · The Journal of Clinical Pharmacology · 21

PDF

Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults

2020 · Azmi Nasser, Shamia L. Faison, et al. · The Journal of Clinical Psychiatry · 20

PDF

Impact of Paroxetine, a Strong CYP2D6 Inhibitor, on SPN‐812 (Viloxazine Extended‐Release) Pharmacokinetics in Healthy Adults

2021 · Zhao Wang, Alisa R. Kosheleff, et al. · Clinical Pharmacology in Drug Development · 16

Oxcarbazepine: Clinical Development Program

1994 · Stefan Schwabe · Epilepsia · 14

A Double-Blind, Randomized Study of Extended-Release Molindone for Impulsive Aggression in ADHD

2020 · Gianpiera Ceresoli-Borroni, Azmi Nasser, et al. · Journal of Attention Disorders · 10

A proposed anti-maladaptive aggression agent classification: improving our approach to treating impulsive aggression

2019 · Adelaide S. Robb, Stefan Schwabe, et al. · Postgraduate Medicine · 9

PDF

112 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P302): Efficacy and Safety of Extended-Release Viloxazine in Adolescents with ADHD

2020 · Azmi Nasser, Joseph T. Hull, et al. · CNS Spectrums · 8

PDF

Works count: 56

Citation count: 1,848

H-index: 20

I10-index: 23